D-Glutamate

D-Glutamate

SCHEMBL4387193

NC(CCC(=O)NC(Cc1ccccc1)C(=O)O)C(=O)O.NC(CCC(=O)O)C(=O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NAALAD2 Q9Y3Q0 3/20 0.64
ACE P12821 4/20 0.54
ALPI P09923 1/20 0.51
PKM P14618 1/20 0.51
PTGS1 P23219 1/20 0.51
XIAP P98170 1/20 0.51
SLC7A5 Q01650 1/20 0.51
FOLH1 Q04609 2/20 0.50
MME P08473 2/20 0.50
LTA4H P09960 1/20 0.50
CPA3 P15088 1/20 0.50
SLC15A1 P46059 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glutamic Acid SCHEMBL4387195 1.00 NAALAD2 (0.64) NAALAD2ACEALPIPKMPTGS1
SCHEMBL9628000 0.96 ACE (0.58) NAALAD2ACEALPIPKMPTGS1
SCHEMBL18222588 0.96 ACE (0.58) NAALAD2ACEALPIPKMPTGS1
SCHEMBL161657 0.96 ACE (0.58) NAALAD2ACEALPIPKMPTGS1
SCHEMBL161658 0.96 ACE (0.58) NAALAD2ACEALPIPKMPTGS1
SCHEMBL30803739 0.94 NAALAD2 (0.61) NAALAD2ACEMME
SCHEMBL25409107 0.90 NAALAD2 (0.57) NAALAD2ACEMME
Methylmalonic Acid SCHEMBL29577852 0.90 ACE (0.52) NAALAD2ACEALPIPKMPTGS1
D-Glutamate SCHEMBL4396908 0.90 NAALAD2 (0.66) NAALAD2ACESLC7A5FOLH1MME
Glutamic Acid SCHEMBL4396913 0.90 NAALAD2 (0.66) NAALAD2ACESLC7A5FOLH1MME

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10175233-B2 Biomarkers for cardiovascular diseases and methods using the same METABOLON, INC. (US) 2019-01-08 US disclosed
US-20160178620-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2016-06-23 US disclosed
US-9250225-B2 Biomarkers for insulin resistance and methods using the same METABOLON, INC. (US) 2016-02-02 US disclosed
US-20150005195-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2015-01-01 US disclosed
US-8809008-B2 Biomarkers for impaired glucose tolerance and methods using the same METABOLON, INC. (US) 2014-08-19 US disclosed
US-20130338031-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. 2013-12-19 US disclosed
US-20120208215-A1 Biomarkers for Pre-Diabetes, Cardiovascular Diseases, and Other Metabolic-Syndrome Related Disorders and Methods Using the Same METABOLON, INC. (US) 2012-08-16 US disclosed
US-8187830-B2 Method for determining insulin sensitivity with biomarkers METABOLON, INC. (US) 2012-05-29 US disclosed
US-20090155826-A1 Biomarkers for pre-diabetes, cardiovascular diseases, and other metabolic-syndrome related disorders and methods using the same METABOLON, INC. (US) 2009-06-18 US disclosed